Combination of Cordycepin and Apatinib Synergistically Inhibits NSCLC Cells by Down-Regulating VEGF/PI3K/Akt Signaling Pathway
BackgroundThe application of apatinib is immensely limited by its acquired drug resistance. This research investigates whether cordycepin, a component from Cordyceps could synergize with apatinib to improve its anticancer effect on non-small cell lung cancer (NSCLC) cells.MethodsThe NSCLC cell lines...
Main Authors: | Xiaozhong Liao, Lanting Tao, Wei Guo, Zhuo-Xun Wu, Haiyan Du, Jing Wang, Jue Zhang, Hanrui Chen, Zhe-Sheng Chen, Lizhu Lin, Lingling Sun |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-09-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2020.01732/full |
Similar Items
-
Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway
by: Yong-An Song, et al.
Published: (2019-05-01) -
Cordycepin augments the chemosensitivity of osteosarcoma to cisplatin by activating AMPK and suppressing the AKT signaling pathway
by: Hong-Bo Li, et al.
Published: (2021-12-01) -
The apatinib and pemetrexed combination has antitumor and antiangiogenic effects against NSCLC
by: Zhou Ling, et al.
Published: (2023-03-01) -
Cordycepin Reverses Cisplatin Resistance in Non-small Cell Lung Cancer by Activating AMPK and Inhibiting AKT Signaling Pathway
by: Xiao-Zhong Liao, et al.
Published: (2021-01-01) -
Antitumor Mechanism and Therapeutic Potential of Cordycepin Derivatives
by: Linlin Cui, et al.
Published: (2024-01-01)